New York, NY (PRWEB) May 15, 2012
Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms, has released the syndicated “TrendsmemeTM Report: Virology”. It describes the rapidly increasing momentum in the virology therapeutic category pipelines intended to beat competition, and gives details about the bio-tech and pharma firms involved, including important acquisitions of smaller firms by major players to bolster their positioning in the competition to lead in the treatment of HIV, HCV and HPV. Some strategic acquisitions described are: the January 2011 purchase of Pharmasset by Gilead, Roche’s October 2011 purchase of Anadys Pharmaceuticals, and this February Bristol-Myers Squibb’s purchase of Inhibitex. Merck also is reportedly exploring purchase of Indenix with it’s IDX-184, which is doing well in clinical trials.
Other topics in the report discuss: Gilead’s combination once-daily, single-tablet regimen QUAD pill’s potential to change the course of HIV treatment if FDA approved; Abbott’s ABT-450 drug, on fast-track FDA approval, which might challenge Merck’s boceprevir and Vertex’s telaprevir, the current cutting-edge therapeutics for HCV treatment; and, as reported prospects of treatment leaders continue to change, the Gilead HCV pipeline drug GS-7977, acquired in the buyout of Pharmasset, which might challenge Abbott’s ABT-450 if it enters the market in a few years. Also reported, Merck’s Gardasil and GSK’s Cervarix continue to compete for dominance in the HPV market, while Merck is developing a broad-coverage follow-on HPV vaccine.
Medmeme CEO Mahesh Naithani explains: “The virology topics of HIV, HCV, and HPV demonstrate well how our database works. First we gather information from all relevant medical and science sources, from 60,000 plus URLs worldwide; the discrete 2009-2011 information on developments and market trends in virology. It’s exactly what’s needed by all departments in about two dozen bio-tech and pharmaceutical companies; by their publication managers, medical and brand directors, information services, R&D professionals, and others too such as medical experts and thought leaders. It helps bio-tech and pharma people focus on future opportunities that should be in their strategic planning. Actually, it works the same for all topics, but virology represents a particularly narrow focus. We gather the information. We normalize it to fit it in where it goes in our database, disambiguate it to weed out duplication, integrate it based on narrow definition, then analyze it to produce exactly what these professionals want to see in the report about each indication. Currently, this virology therapeutic category has experienced significant changes in what is going on, who is doing it, the competitive positioning among players. That’s what the report efficiently spells out.”
The intention of MedMeme in publishing the TrendsmemeTM Report is to bring all parties interested up-to-date information on the status of activity in the virology therapeutic category, particularly trends in HIV, HCV, and HPV developments and treatments. Companies mentioned in the report are classified by the character and strength of their involvement with virology treatments. There are seven companies easily selected to classify as dominant companies. They are: Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co, Roche, and Vertex Pharmaceuticals. Another eight company’s activitities should be watched closely. They are: Achillion, Advaxis Pharmaceuticals, GeoVax, Idenix Pharmaceutical, Inovio, Isa Pharmaceuticals, Progenics Pharmaceuticals, and Sangamo BioSciences. And not to be missed are activities at Pfizer, Boehringer-Ingelheim, Janssen, Daiichi Sankyo, Japan Vaccine Co, and Centocor Ortho Biotech.
The syndicated TrendsmemeTM Report : Virology can be purchased separately, or, along with other MedMeme reports by series at discounted pricing. To learn more, see http://www.medmeme.com/reports, or contact us.
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595